Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML18 trial in older patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome
ISRCTN31682779Phase 3Completed
- Sponsor
- Cardiff University
- Start
- Oct 2013
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemtuzumab ozogamicin, daunorubicin + cytarabine liposome, quizartinib, daunorubicin, cytarabine and 3 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (11 arms), sponsored by Cardiff University. Primary endpoints: Overall survival, Event-free survival and 4 more. Started Oct 2013; status: completed.
02
Drugs
gemtuzumab ozogamicindaunorubicin + cytarabine liposomequizartinibdaunorubicincytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ISRCTN31682779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN31682779.